MTARC1 and fatty liver disease: Recent studies, such as that by Jones et al. (2024), have reinforced the protective role of MTARC1, showing that carriers of the rs2642438 variant in murine models with MASH showed weight loss, reduced hepatic steatosis, lower oxidative stress, and reduced fibrogenesis markers [25].